X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs STERLING BIOTECH - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA STERLING BIOTECH ABBOTT INDIA/
STERLING BIOTECH
 
P/E (TTM) x 40.2 -0.4 - View Chart
P/BV x 9.5 0.0 59,143.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   STERLING BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
STERLING BIOTECH
Dec-13
ABBOTT INDIA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,11011 58,190.5%   
Low Rs3,9963 117,529.4%   
Sales per share (Unadj.) Rs1,552.226.8 5,790.5%  
Earnings per share (Unadj.) Rs188.8-15.0 -1,262.3%  
Cash flow per share (Unadj.) Rs196.4-5.5 -3,595.7%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.654.9 1,451.5%  
Shares outstanding (eoy) m21.25267.87 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,255.6%   
Avg P/E ratio x26.8-0.5 -5,759.6%  
P/CF ratio (eoy) x25.7-1.3 -2,022.0%  
Price / Book Value ratio x6.30.1 5,009.1%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,862 5,767.7%   
No. of employees `0003.31.4 245.3%   
Total wages/salary Rs m3,937547 720.0%   
Avg. sales/employee Rs Th9,929.35,303.3 187.2%   
Avg. wages/employee Rs Th1,185.1403.8 293.5%   
Avg. net profit/employee Rs Th1,207.7-2,959.0 -40.8%   
INCOME DATA
Net Sales Rs m32,9857,181 459.4%  
Other income Rs m1,17043 2,746.2%   
Total revenues Rs m34,1557,223 472.8%   
Gross profit Rs m5,245947 553.9%  
Depreciation Rs m1622,543 6.4%   
Interest Rs m384,377 0.9%   
Profit before tax Rs m6,215-5,931 -104.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203-1,924 -114.5%   
Profit after tax Rs m4,012-4,007 -100.1%  
Gross profit margin %15.913.2 120.6%  
Effective tax rate %35.432.4 109.2%   
Net profit margin %12.2-55.8 -21.8%  
BALANCE SHEET DATA
Current assets Rs m22,65514,335 158.0%   
Current liabilities Rs m6,68149,809 13.4%   
Net working cap to sales %48.4-494.0 -9.8%  
Current ratio x3.40.3 1,178.3%  
Inventory Days Days65403 16.1%  
Debtors Days Days29171 17.1%  
Net fixed assets Rs m83555,432 1.5%   
Share capital Rs m213268 79.3%   
"Free" reserves Rs m16,71513,935 119.9%   
Net worth Rs m16,92814,701 115.1%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m24,16273,988 32.7%  
Interest coverage x163.7-0.4 -46,115.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.40.1 1,406.6%   
Return on assets %16.80.5 3,346.7%  
Return on equity %23.7-27.3 -87.0%  
Return on capital %36.9-6.4 -574.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m3691,860 19.8%   
Fx outflow Rs m3,80725 15,293.6%   
Net fx Rs m-3,4381,835 -187.4%   
CASH FLOW
From Operations Rs m1,5271,719 88.8%  
From Investments Rs m-2,148-3,148 68.2%  
From Financial Activity Rs m-1,0241,426 -71.8%  
Net Cashflow Rs m-1,646-3 48,400.0%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.0 -  
FIIs % 0.1 9.9 1.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.1 39.3 43.5%  
Shareholders   18,270 21,482 85.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   WOCKHARDT LTD.  J.B.CHEMICALS  SUN PHARMA  STRIDES SHASUN LTD  GLENMARK PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 16, 2018 03:07 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS